After hours: September 18 at 7:59 PM EDT Loading Chart for MRK ...

Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...

Merck & Co.’s best-selling drug Keytruda helped ... The findings, presented Sunday at the European Society for Medical Oncology Congress in Barcelona, show the initial benefits seen with ...

In 2021, the FDA blasted Merck for using a premature endpoint to ... The results will be presented at the European Society for Medical Oncology (ESMO) 2024 annual meeting. The overall survival ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

ADCs have emerged as one key part of Merck's drive to diversify its cancer pipeline, for example with a $1 billion investment in Seagen in 2020 that gave it rights to the biotech's LIV-1-targeting ...

Analysts see big upside for these undervalued health care stocks.

Executive Editor David Carnoy has been a leading member of CNET's Reviews team since 2000. He covers the gamut of gadgets and is a notable reviewer of mobile accessories and portable audio ...